Aprea Therapeutics, Inc. (NASDAQ:APRE) Short Interest Up 28.0% in March

Aprea Therapeutics, Inc. (NASDAQ:APRE) saw a large increase in short interest in the month of March. As of March 15th, there was short interest totalling 55,700 shares, an increase of 28.0% from the February 28th total of 43,500 shares. Approximately 1.2% of the company’s stock are sold short. Based on an average trading volume of 28,800 shares, the short-interest ratio is currently 1.9 days.

Aprea Therapeutics Price Performance

Shares of Aprea Therapeutics stock opened at $2.04 on Tuesday. The stock has a market cap of $11.20 million, a price-to-earnings ratio of -0.73 and a beta of 0.82. Aprea Therapeutics has a 1 year low of $2.02 and a 1 year high of $6.70. The firm’s 50-day moving average is $2.99 and its 200 day moving average is $3.22.

Aprea Therapeutics (NASDAQ:APRE) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.49) EPS for the quarter, beating analysts’ consensus estimates of ($0.69) by $0.20. Aprea Therapeutics had a negative net margin of 1,029.50% and a negative return on equity of 57.86%. The firm had revenue of $0.21 million for the quarter, compared to analysts’ expectations of $0.15 million. On average, equities analysts expect that Aprea Therapeutics will post -2.55 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on APRE. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Aprea Therapeutics in a research note on Wednesday, January 15th. Wedbush reaffirmed an “outperform” rating and set a $11.00 price objective on shares of Aprea Therapeutics in a research report on Tuesday, March 25th.

Institutional Trading of Aprea Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of APRE. BNP Paribas Financial Markets bought a new position in shares of Aprea Therapeutics during the fourth quarter valued at $43,000. LPL Financial LLC bought a new position in Aprea Therapeutics during the 4th quarter valued at about $53,000. Landscape Capital Management L.L.C. purchased a new stake in shares of Aprea Therapeutics during the 4th quarter valued at about $116,000. Finally, Stonepine Capital Management LLC grew its stake in shares of Aprea Therapeutics by 8.8% in the fourth quarter. Stonepine Capital Management LLC now owns 149,221 shares of the company’s stock worth $491,000 after acquiring an additional 12,047 shares during the period. Institutional investors own 34.19% of the company’s stock.

Aprea Therapeutics Company Profile

Aprea Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors.